Low-Dose Decitabine Vs Best Supportive Care In Older Patients With AML and Low Blast Counts: Results Of a Subgroup Analysis Of The Randomized Phase III Study 06011 Of The EORTC Leukemia Cooperative Group and German MDS Study Group

被引：3
|
作者：
Becker, Heiko
Suciu, Stefan
Rueter, Bjorn
Platzbecker, Uwe
Giagounidis, Aristoteles
Selleslag, Dominik
Labar, Boris
Germing, Ulrich
Salih, Helmut R.
Muus, Petra
Pfluger, Karl-Heinz
Hagemeijer, Anne
Schaefer, Hans-Eckart
Baron, Frederic
Ganser, Arnold
Aul, Carlo
de Witte, Theo
Wijermans, Pierre W.
Luebbert, Michael
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.1452.1452
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1452
引用
收藏
页数：2
相关论文
共 48 条
  • [21] Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group
    H Zwierzina
    S Suciu
    J Loeffler-Ragg
    R Neuwirtova
    P Fenaux
    M Beksac
    J Harousseau
    V Nuessler
    J Cermak
    G Solbu
    R Willemze
    T de Witte
    S Amadori
    Leukemia, 2005, 19 : 1929 - 1933
  • [22] Phase II-III Study of Gemtuzumab Ozogamicin Monotherapy versus Best Supportive Care in Older Patients with Newly Diagnosed AML Unfit for Intensive Chemotherapy: First Results of the EORTC-GIMEMA AML-19 Trial
    Amadori, Sergio
    Suciu, Stefan
    Selleslag, Dominik
    Alimena, Giuliana
    Baila, Liliana
    Rizzoli, Vittorio
    Rossi, Giuseppe
    Gaidano, Gianluca
    Magro, Domenico
    Torelli, Giuseppe
    Muus, Petra
    Venditti, Adriano
    Cacciola, Emma
    Lauria, Francesco
    Beeldens, Filip
    Vignetti, Marco
    de Witte, Theo
    BLOOD, 2008, 112 (11) : 282 - 283
  • [23] 10-day decitabine vs. standard induction, followed by allogeneic stem cell transplantation (HSCT) in AML patients ≥ 60 years: a randomized phase III intergroup study by the EORTC Leukemia Group, GIMEMA, CELG, and GMDS-SG
    Luebbert, M.
    Wijermans, P.
    Kicinski, M.
    Chantepie, S.
    Van der Velden, W.
    Noppeney, R.
    Griskevicius, L.
    Neubauer, A.
    Crysandt, M.
    Vrhovac, R.
    Luppi, M.
    Fuhrmann, S.
    Audisio, E.
    Candoni, A.
    Legrand, O.
    Foa, R.
    Gaidano, G.
    Van Lammeren-Venema, D.
    Posthuma, E. F.
    Hoogendoorn, M.
    Giraut, A.
    Stevens-Kroef, M.
    Jansen, J.
    Ammatuna, E.
    Vilque, J. P.
    Wasch, R.
    Becker, H.
    Blijlevens, N.
    Duhrsen, U.
    Baron, F.
    Suciu, S.
    Amadori, S.
    Venditti, A.
    Huls, G.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 264 - 264
  • [24] High-vs low-dose cytarabine combined with interferon alfa in patients with first chronic phase chronic myeloid leukemia. A prospective randomized phase III study
    W. Deenik
    B. van der Holt
    G. E. G. Verhoef
    A. V. M. B. Schattenberg
    L. F. Verdonck
    S. M. G. J. Daenen
    P. Zachée
    P. H. M. Westveer
    W. M. Smit
    S. Wittebol
    H. C. Schouten
    B. Löwenberg
    G. J. Ossenkoppele
    J. J. Cornelissen
    Annals of Hematology, 2007, 86 : 117 - 125
  • [25] High-vs low-dose cytarabine combined with interferon alfa in patients with first chronic phase chronic myeloid leukemia.: A prospective randomized phase III study
    Deenik, W.
    van der Holt, B.
    Verhoef, G. E. G.
    Schattenberg, A. V. M. B.
    Verdonck, L. F.
    Daenen, S. M. G. J.
    Zachee, P.
    Westveer, P. H. M.
    Smit, W. M.
    Wittebol, S.
    Schouten, H. C.
    Lowenberg, B.
    Ossenkoppele, G. J.
    Cornelissen, J. J.
    ANNALS OF HEMATOLOGY, 2007, 86 (02) : 117 - 125
  • [26] Improved Overall Survival with Gemtuzumab Ozogamicin (GO) Compared with Best Supportive Care (BSC) in Elderly Patients with Untreated Acute Myeloid Leukemia (AML) Not Considered Fit for Intensive Chemotherapy: Final Results from the Randomized Phase III Study (AML-19) of the EORTC and Gimema Leukemia Groups
    Amadori, Sergio
    Suciu, Stefan
    Selleslag, Dominik
    Rossetti, Elena
    Gaidano, Gianluca
    Musso, Maurizio
    Annino, Luciana
    Venditti, Adriano
    Magro, Domenico
    de Fabritiis, Paolo
    Muus, Petra
    Alimena, Giuliana
    Mancini, Marco
    Hagemeijer, Anne
    Cotugno, Francesca
    Vignetti, Marco
    Fazi, Paola
    Meert, Liv
    Ramadan, Safaa M.
    Willemze, Roelof
    de Witte, Theo
    Baron, Frederic
    BLOOD, 2014, 124 (21)
  • [27] Treatment of relapse of AML and MDS after allogeneic stem cell transplantation using low-dose chemotherapy, donor PBSC and GMCSF: Final results from a prospective, multicenter phase II trial by the German cooperative transplant group
    Schmid, Christoph
    Tischer, Johanna
    Steljes, Matthias
    Schleuning, Michael
    Schwerdtfeger, Rainer
    Hegenbart, Ute
    Schubert, Joerg
    Vogel, Wichard
    Gruhn, Berd
    Lallinger, Christiane
    Ledderose, Georg
    Bornhaeuser, Martin
    Kienast, Joachim
    Kolb, Hans-Jochem
    BLOOD, 2007, 110 (11) : 492A - 492A
  • [28] Low-dose fludarabine with or without darbepoetin alfa in patients with chronic lymphocytic leukemia and comorbidity: primary results of the CLL9 trial of the German CLL Study Group
    Goede, Valentin
    Busch, Raymonde
    Bahlo, Jasmin
    Chataline, Viktoria
    Kremers, Stephan
    Mueller, Lothar
    Reschke, Daniel
    Schlag, Rudolf
    Schmidt, Burkhard
    Vehling-Kaiser, Ursula
    Wedding, Ulrich
    Stilgenbauer, Stefan
    Hallek, Michael
    LEUKEMIA & LYMPHOMA, 2016, 57 (03) : 596 - 603
  • [29] Continued low-dose decitabine (DAC) is an active first-line treatment.: In all cytogenetic subgroups of older AML patients:: Results of the FR00331 multicenter phase II study
    Luebbert, Michael
    Rueter, Bjorn
    Claus, Rainer
    Schmid, Mathias
    Germing, Ulrich
    Eimeracher, Hartmut
    Ganser, Arnold
    Platzbecker, Uwe
    Galm, Oliver
    Brugger, Wolfram
    Heil, Gerhard
    Wijermans, Pierre W.
    Pfeifer, Dietmar
    Schmoor, Claudia
    Doehner, Hartmut
    BLOOD, 2007, 110 (11) : 95A - 95A
  • [30] LOW-DOSE GCSF PROPHYLAXIS IS AS EFFECTIVE AS STANDARD-DOSE IN PEDIATRIC CANCER PATIENTS RECEIVING MYELOSUPPRESSIVE CHEMOTHERAPY A PROSPECTIVE RANDOMIZED OPEN LABELED PARALLEL GROUP PHASE III STUDY
    Arora, Brijesh
    Kurkure, P. A.
    Gulia, S.
    Dongre, A.
    Paradkar, A.
    Agarwal, P.
    Pai, S. K.
    Havaldar, R.
    Kannan, S.
    Banavali, S. D.
    PEDIATRIC BLOOD & CANCER, 2010, 55 (05) : 824 - 824
12345